Item 1.01
Entry into a Material Definitive Agreement.
As previously disclosed, on December 6, 2016, 21st Century Oncology Holdings, Inc. (we, our, us or the Company), 21st Century Oncology, Inc. (21C), a subsidiary of the Company, and certain of the Companys other subsidiaries entered into a Forbearance Agreement relating to the Companys indenture and a Forbearance Agreement relating to the Companys credit agreement (collectively, the Forbearance Agreements), with certain of 21Cs noteholders and lenders, respectively. The Forbearance Agreements were subsequently amended on December 15, 2016 and on January 15, 2017.
Effective as of January 31, 2017, we entered into amendments to the Forbearance Agreements (collectively, the Amendments) to, among other things, provide that the noteholders and lenders party thereto will forbear, subject to important exceptions, until the earlier of March 10, 2017 and the occurrence of certain events (as described in the Forbearance Agreements) from exercising any rights and remedies under 21Cs indenture, notes or credit agreement, as applicable, on account of certain events of default.
In addition, effective as of January 31, 2017, Medical Developers, LLC, an indirect wholly owned subsidiary of the Company and certain of its affiliates, entered into an amendment to the MDL Credit and Guarantee Agreement to extend the maturity date from January 31, 2017 to March 10, 2017.
2